Your shopping cart is currently empty

DNDI-0690 is a potent and orally active analogue of DNDI-VL-2098, demonstrating significant efficacy against cutaneous leishmaniasis (CL). It exhibits notable in vitro activity against Leishmania parasites responsible for CL, with an EC50 of 0.17 μM for visceral leishmaniasis and an EC50 of less than 5 μM for the causative parasites of CL. Additionally, DNDI-0690 is effective in a L. major CL mouse model and is applicable for research in CL.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | DNDI-0690 is a potent and orally active analogue of DNDI-VL-2098, demonstrating significant efficacy against cutaneous leishmaniasis (CL). It exhibits notable in vitro activity against Leishmania parasites responsible for CL, with an EC50 of 0.17 μM for visceral leishmaniasis and an EC50 of less than 5 μM for the causative parasites of CL. Additionally, DNDI-0690 is effective in a L. major CL mouse model and is applicable for research in CL. |
| Molecular Weight | 370.34 |
| Formula | C18H15FN4O4 |
| Cas No. | 2097881-13-3 |
| Smiles | C(OC=1C=CC(=NC1)C2=CC=C(F)C=C2)[C@@H]3OC=4N(C=C(N(=O)=O)N4)CC3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.